In recent years, several anti-obesity agents have become available, such as glucagon-like peptide-1 receptor agonists (GLP-1 RA, i.e. liraglutide or semaglutide), and naltrexone-bupropion (NB). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.